Aa
new etv resistance mutant found (it also shares lam, adv res)
Received 11 August 2011; revised 14 October 2011; Accepted 18 October 2011. Available online 9 November 2011.
Abstract
Background
Prolonged antiviral treatment results in selection and accumulation of resistant strains in quasispecies pool in hepatitis B virus (HBV) infection.
Objectives
The aim of this study was to characterise a novel HBV pattern which shows resistance to lamivudine, adefovir dipivoxil and entecavir using in vitro phenoyping assay.
Study design
A male 36 years old patient diagnosed with anti HBe-positive chronic hepatitis B (CHB) had received lamivudine treatment for 7 years following an initial unsuccessfull interferon treatment. The therapy had been switched to adefovir and then to entecavir when breakthrough occcured during each treatment. This led only to a temporary HBV DNA decline which soon was followed by viral breakthrough despite the lack of known entecavir resistance mutations. Patient died after 9 months of entecavir treatment from liver failure. A total of 434 clones from 6 different serum samples were analysed retrospectively. HBV genomes bearing mutation patterns suggestive of antiviral resistance were analysed by in vitro phenotyping assay.
Results
Dominance of a clone carrying L80LV, L91I, M204I, S219A, N238D, Y245H changes was detected in the last serum sample of the patient just before his death. This pattern displayed 30.4 fold resistance to entecavir when compared with the wild type HBV by in vitro phenotyping assay.
Conclusion
A novel mutation pattern showing a high degree of resistance to entecavir was documented. In this pattern, the S219A and Y245H mutations mainly seem to contribute to the emergence of ETV resistance.
Abstract
Background
Prolonged antiviral treatment results in selection and accumulation of resistant strains in quasispecies pool in hepatitis B virus (HBV) infection.
Objectives
The aim of this study was to characterise a novel HBV pattern which shows resistance to lamivudine, adefovir dipivoxil and entecavir using in vitro phenoyping assay.
Study design
A male 36 years old patient diagnosed with anti HBe-positive chronic hepatitis B (CHB) had received lamivudine treatment for 7 years following an initial unsuccessfull interferon treatment. The therapy had been switched to adefovir and then to entecavir when breakthrough occcured during each treatment. This led only to a temporary HBV DNA decline which soon was followed by viral breakthrough despite the lack of known entecavir resistance mutations. Patient died after 9 months of entecavir treatment from liver failure. A total of 434 clones from 6 different serum samples were analysed retrospectively. HBV genomes bearing mutation patterns suggestive of antiviral resistance were analysed by in vitro phenotyping assay.
Results
Dominance of a clone carrying L80LV, L91I, M204I, S219A, N238D, Y245H changes was detected in the last serum sample of the patient just before his death. This pattern displayed 30.4 fold resistance to entecavir when compared with the wild type HBV by in vitro phenotyping assay.
Conclusion
A novel mutation pattern showing a high degree of resistance to entecavir was documented. In this pattern, the S219A and Y245H mutations mainly seem to contribute to the emergence of ETV resistance.
It is well known (now) that Ent is not efficacious as a rescue therapy for LAM resistance. This paper highlights a pattern of mutations that seems to confer 30 fold increase to resistance to ENT in testing in test-tube. It is a warning that an accumulation of drug-related mutations may be very dangerous.
Just my opinion.
Just my opinion.
Entecavir (LAM resistant) 6%(1 year) 15%(2 year) 36%(3 year) 46%(4 year) 51%(5 year) 57%(6 year)
From:
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
GASTROENTEROLOGY 2009;137:1593–1608
It is clear that LAM resistance could NOT be rescued by ENT.
Dan
From:
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
GASTROENTEROLOGY 2009;137:1593–1608
It is clear that LAM resistance could NOT be rescued by ENT.
Dan
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
